Previously submitted to: JMIR mHealth and uHealth (no longer under consideration since Aug 12, 2026)
Date Submitted: Mar 8, 2026
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Clinical Effect of a Smartwatch-Based Mobile Health Intervention on Hypertension and Dyslipidemia: A Randomized Controlled Study
ABSTRACT
Background:
Optimal control of hypertension and dyslipidemia remains challenging despite pharmacological advances. Mobile health technologies offering continuous monitoring and personalized feedback may enhance adherence to lifestyle modification.
Objective:
The aim of this study was to evaluate the clinical effectiveness of a smartwatch-based mobile health intervention in patients with hypertension or dyslipidemia.
Methods:
In this prospective, single-center, randomized controlled trial, patients were assigned (1:1) to an intervention group (Galaxy Watch 4 plus a personalized mobile application) or a control group (standard care). The primary endpoint was the proportion of patients achieving either target blood pressure (24-hour mean systolic blood pressure <130 mmHg) or target LDL cholesterol (<130 mg/dL) at 12 weeks.
Results:
Among 110 analyzed patients (56 with hypertension; 76 with dyslipidemia), the primary endpoint did not differ significantly between groups (31.5% vs 21.4%, p>0.05). However, among patients with hypertension, the intervention group demonstrated a greater median reduction in 24-hour mean systolic blood pressure compared with the control group (−1.0 mmHg vs. 5.0 mmHg; p = 0.049), as well as a greater reduction in daytime mean systolic blood pressure (0 mmHg vs. 3.0 mmHg; p = 0.046). In patients with dyslipidemia, neither LDL cholesterol target achievement nor LDL reduction differed significantly between groups.
Conclusions:
A 12-week smartwatch-based intervention significantly improved ambulatory blood pressure metrics compared with standard care but did not significantly alter lipid outcomes. Wearable-supported digital interventions may be effective adjuncts for hemodynamic control, whereas lipid management may require longer or more intensive strategies. Clinical Trial: ClinicalTrials.gov (Identifier: NCT05712070)
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.